Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood cells boost knee pain relief?

NCT ID NCT07784907

Disease control Sponsor: Implai Sp z o.o Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether adding platelet-rich plasma (PRP) made from a person's own blood to a standard hyaluronic acid injection provides better knee pain relief than hyaluronic acid alone. About 100 adults with moderate knee osteoarthritis will receive one injection of either the combination or the standard treatment, and their pain, function, and quality of life will be tracked for 18 months. The goal is to see if the combined approach offers extra benefit in easing the discomfort and stiffness of knee osteoarthritis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A single injection combining hyaluronic acid with the participant's own platelet-rich plasma (PRP), compared with hyaluronic acid alone.
What this could lead to
If the combination works, it could offer a more effective injection therapy for knee osteoarthritis, potentially reducing pain and improving function without surgery.
What could go wrong
This is a small, early-stage study, and the added benefit of PRP over hyaluronic acid alone is not yet proven. Results may not apply to all patients, and injection-related risks like pain or infection exist.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Knee osteoarthritis meeting American College of Rheumatology (ACR) criteria * Kellgren-Lawrence radiographic grade II or III * Pain intensity in the study knee NRS \>= 4 and in the contralateral knee NRS \<= 2 * Written informed consent Exclusion Criteria: * BMI \>= 40 kg/m2 * Surgery of the same or contralateral knee within the previous year * Intra-articular corticosteroid injection into the study joint within 3 months, or hyaluronic acid, platelet-rich plasma or other intra-articular injection therapy within 6 months before enrolment * Systemic corticosteroid use within 2 weeks * Systemic inflammatory or autoimmune disease with joint involvement (rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus, etc.) * Oral corticosteroid treatment * Deep vein thrombosis * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Knee osteoarthritis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Knee osteoarthritis Knee osteoarthritis (knee oa) Knee osteoarthritis (OA) Osteoarthritis (OA) of the knee

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Przychodnia Specjalistyczna Lancet

    RECRUITING

    Chełm, Lublin Voivodeship, 22-100, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.